Home l Blog 1

Advancements in Combating Autoimmune Diseases Through CAR-T Therapies

A recent study showcased at the ASH Annual Meeting highlights the remarkable potential of CD19-targeting chimeric antigen receptor (CAR) T cells in treatment of systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM) and systemic sclerosis (SSc). By harnessing the power of the T-cells or NK cells to specifically target and eliminate autoreactive B cells responsible for autoimmune responses, CAR-T therapies offer promising avenues for more effective and long-lasting treatments.

But how do we ensure the safety and efficacy of these innovative therapies before they reach patients?

At Invivocue, we leveraged the unique capabilities of human B-cell enhancing humanized mice model to delve into SLE pathogenesis. By inducing the mice with Pristane, we created a robust preclinical model that accurately reproduces the human autoreactive B cell activity in auto-antibodies production and the development of SLE symptoms.

Compared to conventional wild-type and spontaneous mouse models.

  1. Responses are relevant to human physiology.

  2. Presence of human immune cells or proteins.

  3. Prediction of Cytokine Release Syndrome (CRS).

  4. Support personalized therapy via specific donor or HLA selection.

Through this revolutionary preclinical model, we expedite efforts to develop novel therapies for autoimmune diseases.

Invivocue is dedicated to propelling this critical work forward, poised to reshape the landscape of autoimmune disease treatment in the future!